Orforglipron Improves Physical Function More Reliably Than Psychosocial Measures in ATTAIN Trials
This prespecified and post-hoc patient-reported outcome analysis of two phase 3 trials shows what oral orforglipron changes in how patients with obesity function, beyond the weight loss already reported.
📅 Journal publication: Dec 2026(online Oct 13, 2026)·Last updated: Nov 9, 2026
Orforglipron boosts physical and psychosocial health in obesity.
Orforglipron showed improvements in both physical and psychosocial functioning in adults with obesity, potentially enhancing quality of life. Participants receiving orforglipron had greater improvements in Health-Related Quality of Life (HRQoL) from baseline to week 72 compared to placebo. Phase 3 trials indicate beneficial effects on quality of life with orforglipron, but as a new drug, further research is needed for solid placement in therapy. Orforglipron may improve physical and psychosocial functioning in adults with obesity.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Look M, Bays H, Le Roux CW, Xavier NA, Allen SE, Jouravskaya I, Stefanski A, Dimitriadis GK, Behrend B, Ye W, Li J, Gibble TH, Houle C
Citation:Look M, Bays H, Le Roux CW, et al. Orforglipron improved physical and psychosocial functioning in adults with obesity: Results from ATTAIN phase 3 randomized trials. Obesity pillars. 2026;20:100347. doi:10.1016/j.obpill.2026.100347